Journals / Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi / 2008 / Cilt: 11 - Sayı: 2

A case with miller fisher syndrome

Miller fisher sendromlu bir olgu sunumu

Pages
86–89
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, it was aimed to report the symptomes, signs, evaluation and treatment methods of a 44 years old male patient with Miller Fisher Syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Miller Fisher Syndrome which is an uncommon variant of Guillain Barre Syndrome, was originally described in 1956 as a kind of polyneuropath that is characterized by a triad of external opthalmoplegia, ataxia and areflexia.
📊
Key Findings & Data:Presence of Anti GQ1b antibodies in the serum and elevated levels of proteins in CSF can be detected in laboratory analysis.
💡
Conclusion & Impact:In this study, it was aimed to report the symptomes, signs, evaluation and treatment methods of a 44 years old male patient with Miller Fisher Syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Miller Fisher Syndrome which is an uncommon variant of Guillain Barre Syndrome, was originally described in 1956 as a kind of polyneuropath that is characterized by a triad of external opthalmoplegia, ataxia and areflexia. Opthalmoplegia, diplopia, pythosis, mydriasis and facial paralysis can be seen as clinical symptoms. On physical examination, limitation of eye movements, especially the lateral gaze, ataxia, absence of deep tendon reflexes, generalized hypoestesia, dysmetria, dysdiadokinesia and preserved motor stregth can be found. Presence of Anti GQ1b antibodies in the serum and elevated levels of proteins in CSF can be detected in laboratory analysis. Sensorial polyneuropathy can be revealed electrophysiologically. In this study, it was aimed to report the symptomes, signs, evaluation and treatment methods of a 44 years old male patient with Miller Fisher Syndrome.

Özet

Guillain Barre Sendromunun nadir bir varyantı olan Miller Fisher Sendromu, ilk kez 1956 yılında tanımlanmış olan eksternal oftalmopleji, ataksi ve arefleksi triadı ile karakterize bir tür polinöropatidir. Hastalığın kliniğinde oftalmaopleji, diplopi, pitozis, midriyazis, fasial paralizi, fizik muayenesinde göz hareketlerinde özellikle dışa bakmada kısıtlılık, ataksi, derin tendon reflekslerinin alınamaması, kas güçlerinin korunması, yaygın hipoestezi, dismetri, disdiadokinezi ve laboratuarında serumda anti GQ1b antikorunun saptanması, BOS proteininde artma ve elektrofizyolojik çalışmalarda sensoryal polinöropati saptanabilir. Bu çalışmada, 44 yaşındaki bir erkek hasta incelenerek Miller Fisher Sendromunun belirti, bulgu, tanı ve tedavi yöntemlerini ortaya koymak amaçlanmıştır.

🔖

Cite This Article

TOK, F., BALABAN, B., TUĞCU, İ. (2008). A case with miller fisher syndrome. Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi, Cilt: 11 - Sayı: 2, 86–89. https://ajindex.com/articles/198300

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Asbury A, Cornblath DR, Assesment of current diagnostic criteria for Guillain-Barre Syndrome. Ann Neurol. 1990;27:21-24
  2. Hughes RA, Rees JH. Clinical and epidemiological features of Guillain Barre syndrome. J Infections Dis. 1997;176:92-98
  3. Halls J, Bredkjaer C, Friis ML. Guillain-Barre syndrome: diagnostic criteria, epidemiology, clinical course and prognosis.Acta Neurol Scand 1988;78:118-122
  4. Bushra JS. Miller-Fisher syndrome: an uncommon acute neuropathy. J Emerg Med 2000;18:427-430
  5. Fisher M. An unusual varient of Acute Idıopatic Polyneuritis (Syndrome of Ophthalmoplegia, Ataxia and Areflexia). N Engl J Med 1956;255:57-65
  6. Willison HJ, O'Hanlon GM. The Immunopathogenesis of Miller Fisher sendrome. Journal of Neuroimmunolgy 1999;100:3-12
  7. Buchwald B, Weishaupt A, Toyka KV, Dude J. Immunoglobulin G from a patient with Miller Fisher syndrome rapidly and reversibly depress evoked quantal release at the neuromuscular junction of mice. Neurosci Lett 1995;201:160-166
  8. Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain Barre syndrome and Miller Fisher sydrome. J Infect Dis 1997;176:150-3
  9. Jacobs BC, Hazenberg MP, van Doorn PA, et al. Crossreactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain Barre or Miller Fisher sydrome. J Infect Dis 1997;175:729-33
  10. Suzuki K, Yuki N, Muramatsu M, Hirata K. Unilateral ophthalmoparesis and limb ataxia associated with anti- GQ1b IgG antibody. J Neurol 2000;247:652-653
  11. Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-679
  12. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher sydrome and Guillain- Barre sydnrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-1917
  13. Sartucci F, Cafforio G, Borghetti D, Domenici L, Orlandi G, Murri L. Electrophysiological evidence by single fiber electromyography of neuromuscular transmission impairment in a case of Miller Fisher syndrome. Neurol Sci 2005;26:125-128
  14. Willison HJ, Yuki N. Peripheral neuropathies and antiglycolipid antibodies. Brain 2002;125:2591-2625
  15. Chiba A, Kusnoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with opthalmoplegia in Miller Fisher Syndrome a